CHARLOTTESVILLE, Virginia and ATHENS, Greeece, December 1 /PRNewswire/ — Biovista Inc. today announced the signing of a new collaboration agreement with the Thalassaemia International Federation (TIF) for the installation and support of its JAnaemia patient record management system. JAnaemia, which has been customized, in this case for beta thalassaemia patients, will be initially installed at … Read More
Press Releases
Biovista announces positive efficacy results in a pre-clinical trial of BVA-201 for Multiple Sclerosis
CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ — Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both … Read More
Biovista Inc. announces positive efficacy results in a pre-clinical trial of its BVA-601 drug for Epilepsy
CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ — Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant … Read More
Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis
CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More
Cempra Pharmaceuticals and Biovista Inc. enter agreement for macrolide CT design support
CHAPEL HILL, N.C. and CHARLOTTESVILLE, Va.–(Business Wire)–Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class. The data generated will be used to better understand the unique benefit/risk characteristics of this important group of … Read More